Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Disorders of Coagulation or Fibrinolysis Poster II

Sunday, December 7, 2008: 6:00 PM-8:00 PM
Hall A (Moscone Center)
Milk Box Misdiagnosis of Von Willebrand Disease Is Common

Thomas Coyle, MD1, Srivalli Gopaluni, MD2*, Nancy Newman, MS2* and Janis Hansen, BS, SH3*

1Medicine, SUNY Upstate Med. Univ., Syracuse, NY
2Medicine, SUNY Upstate Medical University, Syracuse, NY
3Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY

Woundstat™ Topical Hemostat Reverses Clotting Diatheses in Models of Acquired and Congenital Hemophilia

Parthasarathy Madurantakam1*, Gary Bowlin, PhD1* and Keith A. Moskowitz, PhD2

1Biomedical Engineering, Virginia Commonwealth University, Richmond, VA
2TraumaCure, Inc., Bethesda, MD

Pharmacokinetic Evaluation of a Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency

Marilyn J. Manco-Johnson, MD1, Giancarlo Castaman, MD2*, Sandra Fremann, MD3*, Sigurd Knaub, PhD4*, Gavino Piseddu, MD5* and Pier M. Mannucci, MD6*

1Pediatrics, Mountain States Regional Hemophilia and Thrombosis Center, University of Colorado Denver, Aurora, CO
2Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
3Clinical R&D, CSL Behring GmbH, Marburg, Germany
4Research and Development, Behring GmbH, Marburg, Germany
5Centro Emofilia e Trombosi, Ospedale SS Annunziata ASL N° 1-Sassari, Sassari, Italy
6Centro Emofilia e Trombosi Angelo Bianchi Bonomi, Universita Degli Studi di Milano, Milan, Italy

Pharmacokinetics, Coagulation Factor Consumption, and Product Efficacy in Patients Crossing Over from Full-Length FVIII to B-Domain Deleted R-FVIII and Back to Full-Length FVIII

Catherine J Rea, MA, MRCP*, Alex Dunkerley, BA*, Benny Sorensen, MD, Ph.D.* and Savita Rangarajan, MBBS, FRCP, FRCPath

Centre for Haemostasis & Thrombosis, Guy's & St. Thomas' NHS Foundation Trust, London, United Kingdom

Novel Pleiotropic Effects of Thrombin in Regulation of the Metastatic Potential of Human Rhabdomyosarcoma (RMS) Cells

Marcin Wysoczynski, MS* and Mariusz Z Ratajczak, M.D., Ph.D.

James Graham Brown Cancer Center, Stem Cell Institute University of Louisville, Louisville, KY

Identification of Genes Associated with Inhibitor Development in Hemophilia a by Microarray Analysis

Sung Ho Hwang, PhD1*, Hugh C Kim, M.D.2, Hyun Woo Lee, M., D.2*, Ki young Yoo, M.D.3*, Hyon J Kim, M.D.4* and Hye Sun Kim, PhD1*

1Department of Biological Sciences, Ajou University, Suwon, South Korea
2Hematology-Oncology, Ajou University Hospital, Suwon, South Korea
3Korea Hemophilia Foundation Clinic, Seoul, South Korea
4Medical Genetics, Ajou University Hospital, Suwon, South Korea

Cardiovascular Disease in Patients with Hemophilia: Single Centre Experience

Anjali Sharathkumar, MD1, Brandy Trawinski, LPN, BLS2*, J. Michael Soucie, PhD3*, Anne Greist, MD1, Craig Haddix2* and Amy D. Shapiro, MD1

1Indiana Hemophilia & Thrombosis Ctr., Indianapolis, IN
2Indiana Hemophilia and Thrombosis Centre, Indianapolis, IN
3Division of Blood Disorders, Centers for Disease Control & Prevention, Atlanta, GA

Very Rapid Clearance after a Joint Bleed Knee Can Not Prevent Adverse Effects on Cartilage and Synovial Tissue: A Canine in Vivo Study

Nathalie W.D. Jansen, PhD1*, Goris Roosendaal, MD, PhD1*, Marion Wenting2*, Herman A.W. Hazewinkel, PhD3*, Johannes W.J. Bijlsma, MD, PhD2*, Matthias Theobald, MD, PhD1 and Floris P.J.G. Lafeber, PhD2*

1Hematology and Van Creveldkliniek, University Medical Center Utrecht, Utrecht, Netherlands
2Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
3Clinical Sciences of Companion Animals, Utrecht University, Utrecht, Netherlands

Usefulness of Whole Blood Thromboelastography for the Diagnosis and Characterisation of Von Willebrand Disease

Catherine Lambert1* and Cedric R. Hermans, MD, PhD, MRCP2

1Division of Haematology, Cliniques universitaires Saint-Luc, Brussels, Belgium
2Haematology Div., Cliniques Univ. Saint-Luc, Brussels, Belgium

Rituximab for Treatment of Resistant Inhibitors in Severe Haemophilia a: A Consecutive National Cohort

Raina Liesner, MA, MBBChir, MD, MRCP, MRCPCH, F1*, Mary Mathias, BA, MBBS, MRCP, FRCPath1*, John Hanley2*, Russell Keenan, PhD3, David M. Keeling, MD4, Michael Laffan5*, Elizabeth Chalmers6*, Charles R.M. Hay, MD, FRCP, FRCPath7, Rhona Maclean8*, Savita Rangarajan, MBBS, FRCP, FRCPath9, Mike Williams10*, David J. Perry, MD, PhD, FRCP, FRCPath11 and Peter Collins12*

1Great Ormond Street Hospital for Children, Haemophilia Centre,, Haemophilia Comprehensive Center Great Ormond Street Hospital for Children, London, United Kingdom
2Haemostasis and Thrombosis, The Newcastle upon Tyne Hospitals NHS FoundationTrust, Newcastle upon Tyne, United Kingdom
3Dept. of Pediatric Onc. & Hem., Alderhey Children's Hospital, Liverpool, ARRAY(0xc39ff50)
4Oxford Haemophilia and Thrombosis Centre, Oxford, ARRAY(0xa0899f8)
5Haemophilia Centre, Hammersmith Hospital, London
6Haemophilia Centre, Royal Hospital for Sick Children, Glasgow
7Dept. of Clinical Hematology, Manchester Royal Infirmary, Manchester, ARRAY(0xc270a4c)
8Sheffield Haemostasis and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield
9Centre for Haemostasis & Thrombosis, Guy's & St. Thomas' NHS Foundation Trust, London, GBR
10Haematology, Birmingham Children's Hospital NHS Trust, Birmingham, United Kingdom
11Dept. of Haematology, Addenbrooke's NHS Trust, Cambridge, ARRAY(0xc878178)
12Haematology, University Hospital of Wales, Cardiff, United Kingdom

Defining Severity for Rare Factor Deficiencies. Insights from the North American Rare Bleeding Disorder Registry(NARBDR)

Suchitra S Acharya, MD and Donna DiMichele, MD*

Pediatric Hematology/Oncology, Weill Medical College of Cornell University, New York, NY

Kaolin-Activated Thromboelastography in Hemophilia Patients Discriminates Responses to rFVIIa Better Than Tissue Factor

Ru Zhang, MD1*, Dena Yassin2*, Lingyun Ji1*, Robert Miller1*, Diane J. Nugent, MD2 and Guy Young, MD1

1Children's Hospital Los Angeles, Los Angeles, CA
2Children's Hospital of Orange County, Orange, CA

Recombinant Activated Factor VII (rFVIIa) Dosing and Efficacy in the Treatment of Cranial Hemorrhage in Hemophilia Patients with Inhibitors: An Analysis of the Hemophilia and Thrombosis Research Society Registry (HTRS) (2004-2008)

Charles T Nakar, MD1*, David L. Cooper, MD, MBA2* and Donna DiMichele, MD3

1Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
2Medical Affairs, Novo Nordisk Inc., Princeton, NJ
3Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

Performance of a New Global Chromogenic Assay for Protein C Pathway (HemosIL ThromboPath) in the Diagnosis of Lupus Anticoagulant and Antiphospholipid Antibodies

Pierre A. Toulon1, Isabelle Martin-Toutain2*, Jean-Charles Piette3*, Marie-Claude Diemert4* and Annick Ankri2*

1Hematology, CHU Cimiez, Nice, France
2Hematology, GH Pitié-Salpêtrière, Paris, France
3Internal Medicine, GH Pitié-Salpêtrière, Paris, France
4Immunochemistry, GH Pitié-Salpêtrière, Paris, France

Mapping of Conformational Epitopes, and Analyze of the Distribution of Ig Isotypes and Subclasses Using a Semi-Quantitative Multiplex Assay in 6 Cases of Postpartum Acquired Hemophilia

Geraldine Lavigne-Lissalde1*, Priscilla Lapalud2*, Claire Pouplard3*, Claude Granier2*, Jeanne-Yvonne Borg4*, Chantal Rotschild5*, Yves Gruel3 and Jean-François Schved1*

1Hematology-Hemostasis, University Hospital of Montpellier, Hospital St Eloi, Montpellier, France
2CNRS/ BIORAD FRE 3009, Montpellier, France
3Dept. Hematology-Hemostasis, University Hospital of Tours, Tours, France
4Dept. Hematology, Hospital University of Rouen, Rouen, France
5dept. Hematology, Hospital Necker, Paris, France

Cardiovascular Interventions in Patients with Hemophilia and Severe Von Willebrand Disease

Andreas Tiede, MD, PhD1, Sonja R. Alesci, MD2*, Dr. Klamroth, MD3*, Katharina Holstein, MD4*, Manuela Krause, MD5*, Ronald Fischer, MD6*, Ute Scholz, MD7*, Johannes Oldenburg, MD8 and Silvia Horneff, MD9*

1Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
2Johann Wolfgang Goethe University, Frankfurt, Germany
3Hemophilia Center, Vivantes Berlin, Berlin, Germany
4Hematology and Oncology, University of Hamburg, Hamburg, Germany
5Angiology/Haemostaseology, Deutsche Klinik für Diagnostik, 65191, Germany
6Hemostaseology, University of Giessen, Giessen, Germany
7Center of Hemostasis Leipzig, Leipzig, Germany
8Transfusion Medicine and Experimental Haematology, University of Bonn, Bonn, Germany
9Transfusion Medicine and Experimental Hematology, University of Bonn, Bonn, Germany

Deep Venous Thrombosis Screening of Hemophilia Patients with Central Venous Catheters

Carrye R. Cost, MD1*, Kim L. Spencer, MS, RN, CPNP2*, George R. Buchanan, MD1 and Janna M. Journeycake, MD3

1Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
2Children's Medical Center Dallas, Dallas, TX
3University of Texas Southwestern Medical Center at Dallas, Dallas, TX

Successful Control of Refractory Inhibitors in Children with Hemophilia a Using Multiple Agent Immune Modulation

Marilyn J. Manco-Johnson, MD1, Lori Wagner, RN2*, Michael Recht, MD, PhD3, Christine Knoll, MD4*, Susan J. Geraghty, RN, MBA5*, Elizabeth Pounder, PA6* and Neil A. Goldenberg, MD, PhD7*

1Mountain State Regional Hemophilia and Thrombosis Center, University of Colorado, Aurora, CO
2Pediatrics, Phoenix Childrens Hospital, Phoenix, AZ
3Hemophilia Treatment Center, Oregon Health and Science University, Portland, OR
4Hematology, Phoenix Children's Hospital, Phoenix, AZ
5Mountain State Regional Hemophilia and Thrombosis Center, University of Colorado Denver, Aurora, CO
6Dept. of Hem./Onc./BMT, The Children's Hospital, Aurora, CO
7Depts. of Pediatrics and Medicine and Mountain States Regional Hemophilia and Thrombosis Center, Univ. of Colorado Denver and The Children's Hospital, Aurora, CO

Assessment of Plasma Prothrombotic Factors in Patients with Buerger’s Disease

Iwona Hus1*, Bozena Sokolowska1*, Marek Chrapko2*, Aleksandra Nowaczynska1*, Adam Walter-Croneck1*, Kamila Mazurek1*, Magdalena Lewandowska3*, Jacek M. Rolinski4 and Anna Dmoszynska1*

1Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
2Vascular Surgery, Specialist Provincial Hospital in Lublin, Lublin, Poland
3Regional Centre of Blood Donation and Blood Treatment in Lublin, Lublin
4Dept. of Clinical Immunology, Medical Univ. of Lublin, Lublin, Poland

Treatment of Acute Bleeds in Acquired Hemophilia: Analysis from the Hemophilia Research Society (HRS) and Hemophilia and Thrombosis Research Society (HTRS) Registry

Suman Sood, MD1, Barbara A. Konkle, MD1, Craig M. Kessler, MD2, David L Cooper, MD, MBA3* and HRS-HTRS Registry Investigators4*

1Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA
2Georgetown University Medical Center, Washington, DC
3Novo Nordisk Inc., Princeton, NJ
4Hemophilia Treatment Center, Multiple Institutions, Multiple Cities

*signifies non-member of ASH